Sleep Quality After Quetiapine Augmentation in Patients With Treatment-Resistant Depression and Personality Disorders

Abstract

Purpose/Background Quetiapine is a first-line augmenting agent for treatment-resistant depression (TRD) and is used off-label in insomnia. Quetiapine and its active metabolite norquetiapine act mostly on 5-HT2A, 5-HT2C, H1, and D2 as antagonists and on 5-HT1A as partial agonists. Patients with TRD often have comorbid personality disorder (PD), and evidence suggests an association between sleep disturbance and recovery among patients with PD. Here, we aimed to evaluate the effects of quetiapine on sleep in TRD patients with and without PD (PD+/PD−). Methods/Procedures We reviewed health records of 38 patients with TRD (20 TRD/PD+) who had been treated with a pharmacotherapy regimen including quetiapine. Clinical outcomes were determined by comparing changes in sleep items of the Hamilton Depression Rating Scale at the beginning (T0) and after 3 months of an unchanged treatment (T3). Findings/Results Patients with TRD/PD+ and TRD/PD− taking quetiapine showed significant improvement in sleep items from T0 to T3 (P < 0.001, η p 2 ≥ 0.19). There was a significant personality × time interaction for sleep-maintenance insomnia (P = 0.006, η p 2 = 0.23), with TRD/PD+ showing a greater improvement at T3 compared with TRD/PD− (P = 0.01). While exploring other sleep items, no personality × time interaction was found. In the TRD/PD− group, improvement in sleep items was associated with an overall improvement in depressive symptoms (r = 0.55, P = 0.02). Implications/Conclusions Quetiapine induced greater improvements in sleep-maintenance insomnia among TRD/PD+ patients than TRD/PD−. These findings suggest quetiapine could have a therapeutic role for insomnia in PD underscoring a distinct underlying neurobiological mechanism of sleep disturbance in people living with PD.